Profilin-1 phosphorylation directs angiocrine expression and glioblastoma progression through HIF-1α accumulation

Nature Cell Biology

Volumn 16, Issue 5, 2014, Pages 445-456

  Fan, Yi ^a,b   Potdar, Alka A ^a,c   Gong, Yanqing ^a,d   Eswarappa, Sandeepa M ^a   Donnola, Shannon ^a   Lathia, Justin D ^a   Hambardzumyan, Dolores ^a   Rich, Jeremy N ^a   Fox, Paul L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Case Western Reserve University   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOCRINE; ANGIOGENIC FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PROFILIN; PROFILIN I; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN; FIBROBLAST GROWTH FACTOR 2; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 2ALPHA; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PROFILIN 1; VASCULOTROPIN A; VASCULOTROPIN B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOACCUMULATION; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; ENDOTHELIUM CELL; GENETIC MODEL; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR VASCULARIZATION; ANIMAL CELL; ANIMAL TISSUE; CANCER PROGNOSIS; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CELL PROLIFERATION; DISEASE ASSOCIATION; FEMALE; MALE; NUCLEOTIDE SEQUENCE; POSITIVE FEEDBACK; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; TUMOR GROWTH; UBIQUITINATION;

MUS;

ANIMALS; AUTOCRINE COMMUNICATION; BRAIN NEOPLASMS; CAPILLARY PERMEABILITY; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENDOTHELIAL CELLS; FEMALE; GLIOBLASTOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; NEOPLASM GRADING; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROFILINS; RNA INTERFERENCE; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; TUMOR MICROENVIRONMENT; TYROSINE; UP-REGULATION; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84899986078     PISSN: 14657392     EISSN: 14764679     Source Type: Journal    
DOI: 10.1038/ncb2954     Document Type: Article

References (55)

1. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
2. Vaupel, P., Kallinowski, F. & Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 49, 6449-6465 (1989).
3. Joyce, J. A. & Pollard, J. W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 9, 239-252 (2009).
4. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971).
5. Jain, R. K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7, 987-989 (2001).
6. Carmeliet, P. & Jain, R. K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 10, 417-427 (2011).
7. Weis, S. M. & Cheresh, D. A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med. 17, 1359-1370 (2011).
8. Burger, P. C., Vogel, F. S., Green, S. B. & Strike, T. A. Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer 56, 1106-1111 (1985).
9. Johnson, D. R. & O'Neill, B. P. Glioblastoma survival in the United States before and during the temozolomide era. J. Neurooncol. 107, 359-364 (2012).
10. Huse, J. T. & Holland, E. C. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat. Rev. Cancer 10, 319-331 (2010).
11. Kim, K. J. et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844 (1993).
12. Batchelor, T. T. et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95 (2007).
13. Friedman, H. S. et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27, 4733-4740 (2009).
14. Witke, W. The role of profilin complexes in cell motility and other cellular processes. Trends Cell Biol. 14, 461-469 (2004).
15. Fan, Y. et al. Stimulus-dependent phosphorylation of profilin-1 in angiogenesis. Nat. Cell Biol. 14, 1046-1056 (2012).
16. Charles, N. et al. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 6, 141-152 (2010).
17. Galban, S. et al. DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma. PLoS ONE 7, e35857 (2012).
18. McConville, P. et al. Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. Clin. Cancer Res. 13, 2897-2904 (2007).
19. Jain, R. K. Molecular regulation of vessel maturation. Nat. Med. 9, 685-693 (2003).
20. Forsythe, J. A. et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell Biol. 16, 4604-4613 (1996).
21. Calvani, M., Rapisarda, A., Uranchimeg, B., Shoemaker, R. H. & Melillo, G. Hypoxic induction of an HIF-1α-dependent bFGF autocrine loop drives angiogenesis in Human endothelial cells. Blood 107, 2705-2712 (2006).
22. Schofield, C. J. & Ratcliffe, P. J. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol. 5, 343-354 (2004).
23. Min, J. H. et al. Structure of an HIF-1α-pVHL complex: Hydroxyproline recognition in signaling. Science 296, 1886-1889 (2002).
24. Keith, B. & Simon, M. C. Hypoxia-inducible factors, stem cells, and cancer. Cell 129, 465-472 (2007).
25. Semenza, G. L. Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell 5, 405-406 (2004).
26. Plate, K. H., Breier, G., Weich, H. A. & Risau, W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359, 845-848 (1992).
27. Dunn, I. F., Heese, O. & Black, P. M. Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. J. Neurooncol. 50, 121-137 (2000).
28. Nyberg, P., Salo, T. & Kalluri, R. Tumor microenvironment and angiogenesis. Front. Biosci. 13, 6537-6553 (2008).
29. Park, J. H. et al. Gastric epithelial reactive oxygen species prevent normoxic degradation of hypoxia-inducible factor-1alphaup in gastric cancer cells. Clin. Cancer Res. 9, 433-440 (2003)
30. Sumbayev, V. V. LPS-induced Toll-like receptor 4 signalling triggers cross-talk of apoptosis signal-regulating kinase 1 (ASK1) and HIF-1alphaup protein. FEBS Lett. 582, 319-326 (2008).
31. Selak, M. A. et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell 7, 77-85 (2005).
32. Tannahill, G. M. et al. Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature 496, 238-242 (2013).
33. Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C. & Semenza, G. L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alphaup (HIF-1α) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell Biol. 21, 3995-4004 (2001).
34. Li, Y. M. et al. A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 overexpressing cells. Cancer Res. 65, 3257-3263 (2005).
35. Koka, V. et al. Role of Her-2/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme. Am. J. Clin. Oncol. 26, 332-335 (2003).
36. Potti, A. et al. Determination of HER-2/neu overexpression and clinical predictors of survival in a cohort of 347 patients with primary malignant brain tumors. Cancer Invest. 22, 537-544 (2004).
37. Haynik, D. M., Roma, A. A. & Prayson, R. A. HER-2/neu expression in glioblastoma multiforme. Appl. Immunohistochem. Mol. Morphol. 15, 56-58 (2007).
38. Ding, B. S. et al. Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. Nature 468, 310-315 (2010).
39. Ding, B. S. et al. Endothelial-derived angiocrine signals induce and sustain regenerative lung alveolarization. Cell 147, 539-553 (2011).
40. Muramatsu, R. et al. Angiogenesis induced by CNS inflammation promotes neuronal remodeling through vessel-derived prostacyclin. Nat. Med. 18, 1658-1664 (2012).
41. Lu, J. et al. Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of jagged-1. Cancer Cell 23, 171-185 (2013).
42. Lee, S. et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 130, 691-703 (2007).
43. Seghezzi, G. et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothe-lial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J. Cell Biol. 141, 1659-1673 (1998).
44. Butler, J. M., Kobayashi, H. & Rafii, S. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat. Rev. Cancer 10, 138-146 (2010).
45. Kreisl, T. N. et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27, 740-745 (2009).
46. Fan, Y., Gong, Y., Ghosh, P. K., Graham, L. M. & Fox, P. L. Spatial coordination of actin polymerization and ILK-Akt2 activity during endothelial cell migration. Dev. Cell 16, 661-674 (2009).
47. Janke, J. et al. Suppression of tumorigenicity in breast cancer cells by the microfilament protein profilin 1. J. Exp. Med. 191, 1675-1686 (2000).
48. Ding, Z., Gau, D., Deasy, B., Wells, A. & Roy, P. Both actin and polyproline interactions of profilin-1 are required for migration, invasion and capillary morphogenesis of vascular endothelial cells. Exp. Cell Res. 315, 2963-2973 (2009).
49. Venneri, M. A. et al. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 109, 5276-5285 (2007).
50. De Palma, M. et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8, 211-226 (2005).
51. Pyonteck, S. M. et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19, 1264-1272 (2013).
52. Liu, Y. et al. Somatic cell type specific gene transfer reveals a tumor-promoting function for p21(Waf1/Cip1). EMBO J. 26, 4683-4693 (2007).
53. Ciznadija, D., Liu, Y., Pyonteck, S. M., Holland, E. C. & Koff, A. Cyclin D1 and cdk4 mediate development of neurologically destructive oligodendroglioma. Cancer Res. 71, 6174-6183 (2011).
54. Liberzon, A. et al. Molecular signatures database (MSigDB) 30. Bioinformatics 27, 1739-1740 (2011).
55. Benita, Y. et al. An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic Acids Res. 37, 4587-4602 (2009).